My name is Akihiro Osumi and I joined the company in April 2024.

In recent years, minimally invasive surgery, or "surgery that is gentle on the body," has become mainstream in the field of surgery in general. In the field of thoracic surgery, for the increasing number of small lung cancers, we are preserving respiratory function by performing lung segmentectomy, which reduces the extent of resection, and striving to reduce pain by performing surgery with small incisions using a thoracoscope or robot. Based on our experience in many thoracoscope-based and robotic surgeries, we specialize in such minimally invasive surgeries.

Furthermore, at Toronto General Hospital, where I studied abroad, and at Kyoto University Hospital, where I was previously employed, I was involved in numerous lung transplants and extended surgeries, and I am also actively involved in extended surgeries such as airway reconstruction and revascularization.Of course, I also respond quickly to all areas of thoracic surgery, including pneumothorax, empyema, and mediastinal tumors.

In the field of lung cancer, remarkable progress has been made in drug therapy, such as molecular targeted drugs and immune checkpoint inhibitors, and treatment outcomes have improved dramatically. At our hospital, we hold weekly conferences with the respiratory medicine, oncology, and oncology radiology departments, and aim to improve treatment outcomes by providing multidisciplinary treatment that includes not only surgery but also pre- and post-operative drug and radiation therapy depending on the individual patient's condition.

We currently have five thoracic surgeons on staff, and we are confident that our patients can receive treatment with peace of mind. We will continue to strive to provide the safest and best possible treatment to all our patients.